Pacific Biosciences/$PACB
1D1W1MYTD1Y5YMAX
Capital at risk
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
- Ticker
- $PACB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 485
- Headquarters
- Menlo Park, United States
- Website
- www.pacb.com
PACB Metrics
BasicAdvanced
$426M
-
-$0.43
2.32
-
Price and volume
Market cap
$426M
Beta
2.32
52-week high
$2.73
52-week low
$1.07
Average daily volume
6.3M
Financial strength
Current ratio
6.867
Quick ratio
3.895
Long term debt to equity
-21.219
Total debt to equity
-21.351
Interest coverage (TTM)
-72.13%
Profitability
EBITDA (TTM)
-514.995
Gross margin (TTM)
29.44%
Net profit margin (TTM)
-82.49%
Operating margin (TTM)
-111.47%
Effective tax rate (TTM)
-0.63%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-14.07%
Return on equity (TTM)
-929.32%
Valuation
Price to revenue (TTM)
2.622
Price to book
-12.8
Price to tangible book (TTM)
-1.17
Price to free cash flow (TTM)
-3.201
Free cash flow yield (TTM)
-31.24%
Free cash flow per share (TTM)
-0.428
Growth
Revenue change (TTM)
2.02%
Earnings per share change (TTM)
-76.40%
3-year revenue growth (CAGR)
2.91%
10-year revenue growth (CAGR)
5.87%
3-year earnings per share growth (CAGR)
-31.76%
10-year earnings per share growth (CAGR)
-0.66%
What the Analysts think about PACB
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
Analyst projections of the future price of Pacific Biosciences stock.
Bulls say / Bears say
SPRQ-Nx could widen PacBio’s market by lowering the cost of HiFi sequencing. Its global launch supports up to three uses of each SMRT Cell and a $345 list price per whole genome, making larger studies more economical. (PacBio)
Clinical demand is becoming a stronger growth engine. Clinical consumable shipments rose 67% year on year, while EMEA revenue grew 52%, and Revio placements increased to 20 from 15 a year earlier. (Yahoo Finance)
The Basecamp Research agreement could give PacBio a substantial population-scale workload and a high-profile use case in AI-led drug discovery. The Trillion Gene Atlas is expected to involve about 100,000 deeply sequenced samples across 31 countries and five continents. (PacBio)
Near-term growth expectations have weakened. PacBio cut 2026 revenue guidance to $155–165 million from $165–175 million as instrument demand softened and customers adopted SPRQ-Nx more slowly than expected. (Yahoo Finance, PacBio)
The company remains cash-burning and now expects cash-flow breakeven in 2028 rather than by the end of 2027. It ended the second quarter with $236.9 million of cash, cash equivalents and investments, leaving less room for execution mistakes or further investment needs. (Yahoo Finance, PacBio)
PacBio is struggling to monetise placements as strongly as before. Instrument revenue fell 9.9% to $12.8 million despite higher Revio placements, while annualised Revio pull-through fell to about $202,000 from $219,000 and non-GAAP gross margin declined to 36% from 38%. (PacBio)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
PACB Financial Performance
Revenues and expenses
PACB Earnings Performance
Company profitability
Upcoming events
No upcoming events
PACB News
AllArticlesVideos
Funds containing PACB
AllUSDEURGBP
Fund name | Fund size | $PACB weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.04% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.04% |
iShares Healthcare Innovation£DRDR | £1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.